Events / Møder under DSF / Årsmøder / 6. årsmøde 2014

6. årsmøde 2014

Title: Protein Therapeutics

09:30 Registration and coffee

10:00 Introduction to meeting: Ulf Simonsen, Aarhus University

Session 1 Chairmen: Steen Hvass Ingwersen, Jesper Hallas

10.05 Pharmacokinetic models for protein therapeutics. Joseph Balthasar, Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York

10.45 Protein therapeutics and gastrointestinal disease. Mark Ainsworth, Herlev Hospital, Copenhagen.

11.15 Rheumatoid arthritis and protein therapeutics. Lars-Erik Kristensen, University Hospital of Skåne

11.45 Future of protein therapeutics. TBC

12.15 Biosimilars. TBC

Session 2. Free oral communications based on submitted abstracts

13.45

14.00

14.15

Session 3 Posters and Coffee

14.30-15.30 Guided poster tours

Poster A. Chairmen 1:

Poster B Chairmen 2

Poster C Chairmen 3:

Session 4. Workshops

Workshop 1. Medicingennemgang og klinisk relevans. Chairmen: Eva Sædder, AU og Dorthe K. Bonnerup, AU

15.30 Virker medicingennemgang på genindlæggelser og død?

Udgangspunkt i Cochrane Review 2013: Christensen M, Lundh A, Medication review in hospitalised patients to reduce morbidity and mortality. Mikkel Christensen, MD, Bispebjerg Sygehus. Klinisk Farmakologisk Afdeling.

15. 45 Hvilke endepunkter måles på i publicerede studier af medicingennemgang og hvilke effekter ses?

Udgangspunkt i review 2013: Graabaek T, Kjeldsen LJ, Medication reviews by clinical pharmacists at hospitals lead to improved patient outcomes: a systematic review. Trine Graabæk Hansen, Cand.pharm., ph.d. studerende, Sydvestjysk Sygehus Esbjerg.

16.00 Er der enighed om hvad klinisk relevante interventioner i medicingennemgang er?

Udgangspunkt i undersøgelse udført på Rigshospitalet. Christine Tilsted Villesen, Cand.pharm., Sygehusapoteket Region Nordjylland.

16.15 Hvad er klinisk relevante interventioner i medicingennemgang.

Et provokerende indlæg og oplæg til efterfølgende diskussion. Jesper Hallas, MD, Klinisk Farmakolog, SDU, Klinisk Farmakologisk Afdeling.

16.30 Panel diskussion af medicingennemgang og klinisk relevans/effektmål i grupper med efterfølgende opsamling.

1. Hvad er klinisk relevant i medicingennemgang?

2. Hvad har patienten egentlig at skulle have sagt?

3. Hvad med økonomien, er det klinisk relevant?

4. Risikerer vi at skade mere end vi gavner?

Workshop 2. Assessment of toxicological substances in a 3R perspective. Chairmen: Eva Bonefeld-Jørgensen, AU and Ole Bjerrum, KU

15.30: New national 3R center / Status and impact of 3 R regulations and current toxicology studies at the National Food Institute:.(“Predictability of in vitro toxicology testing methods compared to animal testing”Christine Nellemann, DTU

15.55 Testing of Drug Candidates: How good is the predictability of animal toxicologystudies. Helle Northeved, Non-clinical Safety Research, Lundbeck A/S (20 min).

16.15 Replacement of animal studies with emphasis of fetal exposure. Lisbeth E. Knudsen & Line Mathiesen, KU

Panel discussion: Toxicology: Quo vadis?

Are specificity and sensitivity complementary? What can be achieved? In silico testing: How good is it? Needs for toxicologist and safety scientist in DK? Toxicology education in DK?

The DSFTM TOX-working group: Christine Nellemann, Lisbeth Knudsen, Erwin Roggen, Ulla Hass, Anne Marie Vinggaard, Jesper Bo Nielsen, Eva C. Bonefeld-Jørgensen, Helle Northeved, Nikolai G. Nikolov?

Workshop 3. Still open

 Session 5 Hot topics in Danish Pharmacology – based on suggestions from the 5 member societies

Chairmen:

17.10 DSFE. DANBIO.

17.25 DSF – Research in treatment of pain. Ole Bjerrum, KU

17.40 DSK2F -

17.55 DSFTM

18.10 DSKF

18.25 Awards to best poster and best oral communication

Closure of meeting: Ulf Simonsen, Aarhus University

18.30 Drinks at the poster area followed by dinner at the Campus restaurant